AGAMREE® (vamorolone)
Duchenne Muscular Dystrophy (DMD)
Key Facts
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a publicly traded biopharma company dedicated to improving the lives of patients with rare diseases through a combination of strategic acquisitions, in-licensing, and targeted development. The company has successfully commercialized therapies for neuromuscular conditions and maintains a pipeline focused on expanding indications and exploring new therapeutic areas. Its leadership team combines deep commercial and clinical expertise, driving a culture of urgency and empathy centered on patient needs.
View full company profileAbout Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a publicly traded biopharma company dedicated to improving the lives of patients with rare diseases through a combination of strategic acquisitions, in-licensing, and targeted development. The company has successfully commercialized therapies for neuromuscular conditions and maintains a pipeline focused on expanding indications and exploring new therapeutic areas. Its leadership team combines deep commercial and clinical expertise, driving a culture of urgency and empathy centered on patient needs.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AOC Program | Avidity Biosciences | Clinical |
| SRP-9001 (delandistrogene moxeparvovec) | Sarepta Therapeutics | Approved |
| Deramiocel (CAP-1002) | Capricor Therapeutics | Phase 3 |
| RGX-202 | REGENXBIO | Phase 1/2 |
| PBGENE-DMD | Precision BioSciences | Phase 1/2 |
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |